Timothy Price

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4273626/publications.pdf

Version: 2024-02-01

264 papers	19,573 citations	38742 50 h-index	11607 135 g-index
267 all docs	267 docs citations	267 times ranked	20956 citing authors

#	Article	IF	Citations
1	K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 2008, 359, 1757-1765.	27.0	3,353
2	Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine, 2007, 357, 2040-2048.	27.0	1,778
3	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 2019, 575, 217-223.	27.8	1,375
4	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. JAMA - Journal of the American Medical Association, 2010, 304, 1073.	7.4	1,206
5	KRAS^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. New England Journal of Medicine, 2020, 383, 1207-1217.	27.0	1,049
6	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 4706-4713.	1.6	909
7	Sotorasib for Lung Cancers with KRAS p.G12C Mutation. New England Journal of Medicine, 2021, 384, 2371-2381.	27.0	833
8	Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. Journal of Clinical Oncology, 2011, 29, 1465-1471.	1.6	669
9	Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e535-e547.	10.7	418
10	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncology, The, 2014, 15, 569-579.	10.7	384
11	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of Clinical Oncology, 2010, 28, 3191-3198.	1.6	370
12	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncology, The, 2017, 18, 1159-1171.	10.7	293
13	Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients. Journal of Clinical Oncology, 2007, 26, 102-109.	1.6	243
14	Colorectal cancer: Metastases to a single organ. World Journal of Gastroenterology, 2015, 21, 11767.	3.3	233
15	Tokyo Guidelines 2018: management strategies for gallbladder drainage in patients with acute cholecystitis (with videos). Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 87-95.	2.6	220
16	Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. Journal of Clinical Oncology, 2015, 33, 3733-3740.	1.6	217
17	Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 2675-2682.	1.6	198
18	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2019, 269, 520-529.	4.2	189

#	Article	IF	Citations
19	Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Annals of Oncology, 2014, 25, 1506-1516.	1.2	186
20	Final results from a randomized phase 3 study of FOLFIRI Â± panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology, 2014, 25, 107-116.	1.2	182
21	Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis. Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 96-100.	2.6	157
22	Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5469-5479.	7.0	152
23	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncology, The, 2022, 23, 115-124.	10.7	147
24	Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRAS^{G12C} inhibitor, in advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 3003-3003.	1.6	145
25	PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancerâ€"Results from NCIC CTG/AGITG CO.17. Clinical Cancer Research, 2014, 20, 744-753.	7.0	140
26	Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?. Cancer, 2015, 121, 830-835.	4.1	135
27	Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational New Drugs, 2012, 30, 2303-2317.	2.6	133
28	Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. Journal of Clinical Oncology, 2013, 31, 2477-2484.	1.6	122
29	Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 263-270.	8.1	121
30	Hyperammonemia encephalopathy: An important cause of neurological deterioration following chemotherapy. Leukemia and Lymphoma, 2007, 48, 1702-1711.	1.3	117
31	Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancerâ€"20 Years of Progress. Molecular Medicine, 2015, 21, S25-S31.	4.4	113
32	Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. Clinical Cancer Research, 2020, 26, 3662-3670.	7.0	107
33	Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies. Supportive Care in Cancer, 2014, 22, 121-128.	2.2	97
34	Role of Aquaporin 1 Signalling in Cancer Development and Progression. International Journal of Molecular Sciences, 2017, 18, 299.	4.1	95
35	Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Medical Journal of Australia, 2010, 193, 46-52.	1.7	89
36	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta OncolÃ³gica, 2018, 57, 1438-1444.	1.8	78

#	Article	IF	Citations
37	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. International Journal of Cancer, 2021, 148, 1014-1026.	5.1	77
38	A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Investigational New Drugs, 2008, 26, 89-94.	2.6	73
39	Biologic therapies in the metastatic colorectal cancer treatment continuum â€“ Applying current evidence to clinical practice. Cancer Treatment Reviews, 2012, 38, 397-406.	7.7	72
40	Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer, 2014, 110, 648-655.	6.4	71
41	Antiâ€“Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?. Oncologist, 2009, 14, 29-39.	3.7	69
42	Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 2012, 6, 199-209.	3.0	69
43	Survival Differences in Patients With Metastatic Colorectal Cancer and With Single Site Metastatic Disease at Initial Presentation: Results From South Australian Clinical Registry for Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 247-254.	2.3	69
44	Pharmacological blockade of aquaporin-1 water channel by AqB013 restricts migration and invasiveness of colon cancer cells and prevents endothelial tube formation in vitro. Journal of Experimental and Clinical Cancer Research, 2016, 35, 36.	8.6	60
45	Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. The Cochrane Library, 2017, 6, CD007047.	2.8	60
46	Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. Journal of Clinical Oncology, 2021, 39, 17-29.	1.6	58
47	Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Annals of Oncology, 2014, 25, 117-121.	1.2	57
48	Final results and outcomes by prior bevacizumab exposure, skin toxicity,Âand hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. European Journal of Cancer, 2016, 68, 51-59.	2.8	56
49	Postpancreatectomy Acute Pancreatitis (PPAP). Annals of Surgery, 2022, 275, 663-672.	4.2	56
50	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clinical Colorectal Cancer, 2018, 17, e617-e629.	2.3	54
51	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 3568-3568.	1.6	53
52	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. Journal of Clinical Oncology, 2016, 34, 2258-2264.	1.6	52
53	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.. Journal of Clinical Oncology, 2014, 32, 3501-3501.	1.6	51
54	Colorectal Cancer Survival: An Analysis of Patients With Metastatic Disease Synchronous and Metachronous With the Primary Tumor. Clinical Colorectal Cancer, 2014, 13, 87-93.	2.3	50

#	Article	IF	Citations
55	Anti-Angiogenic Properties of Ginsenoside Rg3. Molecules, 2020, 25, 4905.	3.8	50
56	South Australian clinical registry for metastatic colorectal cancer. ANZ Journal of Surgery, 2011, 81, 352-357.	0.7	49
57	Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 5602-5609.	7.0	45
58	Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 2013, 24, 953-960.	1.2	44
59	Targeted therapy for metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 991-1006.	2.4	44
60	Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. British Journal of Cancer, 2016, 114, 505-509.	6.4	43
61	Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 2011, 22, 1834-1838.	1.2	42
62	The Purified Extract from the Medicinal Plant Bacopa monnieri, Bacopaside II, Inhibits Growth of Colon Cancer Cells In Vitro by Inducing Cell Cycle Arrest and Apoptosis. Cells, 2018, 7, 81.	4.1	41
63	A populationâ€based study of metastatic colorectal cancer in individuals aged â‰¥80 years. Cancer, 2013, 119, 722-728.	4.1	39
64	Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. Journal of Breast Cancer, 2019, 22, 341.	1.9	39
65	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.. Journal of Clinical Oncology, 2013, 31, 3531-3531.	1.6	39
66	Survival outcomes for patients with metastatic colorectal cancer (mCRC) based on primary site, right (R) colon versus left (L) colon versus rectal (Rec) primary: Results from the South Australian Registry of mCRC.. Journal of Clinical Oncology, 2014, 32, 3540-3540.	1.6	38
67	Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry. Clinical Colorectal Cancer, 2016, 15, 32-36.	2.3	37
68	Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. Clinical Cancer Research, 2019, 25, 1216-1225.	7.0	35
69	Stereoselective Anti-Cancer Activities of Ginsenoside Rg3 on Triple Negative Breast Cancer Cell Models. Pharmaceuticals, 2019, 12, 117.	3.8	34
70	Prognostic impact and the relevance of <scp>PTEN</scp> copy number alterations in patients with advanced colorectal cancer (<scp>CRC</scp>) receiving bevacizumab. Cancer Medicine, 2013, 2, 277-285.	2.8	33
71	Fc-Î³ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 2435-2444.	7.0	33
72	Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. International Journal of Cancer, 2017, 140, 2183-2191.	5.1	33

#	Article	IF	Citations
73	Cetuximab in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2012, 12, 555-565.	2.4	32
74	Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels. Clinical Proteomics, 2011, 8, 16.	2.1	31
75	Epidemiology of neuroendocrine cancers in an Australian population. Cancer Causes and Control, 2010, 21, 931-938.	1.8	30
76	Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy, 2013, 13, 597-611.	2.4	30
77	Rechallenge With Oxaliplatin and Fluoropyrimidine for Metastatic Colorectal Carcinoma After Prior Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 49-52.	1.3	29
78	The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis. International Journal of Molecular Sciences, 2018, 19, 653.	4.1	29
79	Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. European Journal of Cancer, 2012, 48, 1293-1298.	2.8	28
80	Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therapeutic Advances in Gastroenterology, 2014, 7, 20-37.	3.2	28
81	A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Supportive Care in Cancer, 2014, 22, 513-518.	2.2	28
82	KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model. Gastrointestinal Cancer Research: GCR, 2014, 7, 23-6.	0.7	28
83	Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival?. British Journal of Cancer, 2013, 109, 1338-1343.	6.4	27
84	Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. International Journal of Cancer, 2014, 135, 731-741.	5.1	27
85	Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. Cancer Treatment Reviews, 2018, 66, 1-6.	7.7	26
86	Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. Expert Opinion on Biological Therapy, 2018, 18, 449-457.	3.1	25
87	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.. Journal of Clinical Oncology, 2018, 36, 3500-3500.	1.6	25
88	Bacopasides I and II Act in Synergy to Inhibit the Growth, Migration and Invasion of Breast Cancer Cell Lines. Molecules, 2019, 24, 3539.	3.8	24
89	Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival. BMJ Open, 2019, 9, e031421.	1.9	24
90	Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, LBA387-LBA387.	1.6	24

#	Article	IF	Citations
91	Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women. Frontiers in Oncology, 2016, 6, 241.	2.8	23
92	Oral versus intravenous fluoropyrimidines for colorectal cancer. The Cochrane Library, 2017, 2017, CD008398.	2.8	23
93	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS ONE, 2015, 10, e0135599.	2.5	22
94	CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS^{G12C}, in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2020, 38, 4018-4018.	1.6	22
95	Liver only metastatic disease in patients with metastatic colorectal cancer: Impact of surgery and chemotherapy. Acta OncolÃ³gica, 2013, 52, 1699-1706.	1.8	21
96	Selective internal radiation therapy for liver metastases from colorectal cancer. Cancer Treatment Reviews, 2016, 50, 148-154.	7.7	20
97	Bumetanide-Derived Aquaporin 1 Inhibitors, AqB013 and AqB050 Inhibit Tube Formation of Endothelial Cells through Induction of Apoptosis and Impaired Migration In Vitro. International Journal of Molecular Sciences, 2019, 20, 1818.	4.1	20
98	Selective internal radiation therapy for liver metastases from colorectal cancer. The Cochrane Library, 2009, , CD007045.	2.8	19
99	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Clinical Colorectal Cancer, 2017, 16, e73-e88.	2.3	19
100	Fcâ€gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Medicine, 2018, 7, 5478-5487.	2.8	19
101	Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial. Clinical Colorectal Cancer, 2019, 18, 141-148.	2.3	19
102	Youngâ€onset colorectal cancer is associated with a personal history of type 2 diabetes. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 131-138.	1.1	19
103	Association of <scp>BMI</scp> with overall survival in patients with <scp>mCRC</scp> who received chemotherapy versus <scp>EGFR</scp> and <scp>VEGF</scp>â€targeted therapies. Cancer Medicine, 2015, 4, 1461-1471.	2.8	17
104	Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry. Annals of Surgical Oncology, 2016, 23, 3616-3622.	1.5	16
105	The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. European Journal of Cancer, 2014, 50, 535-543.	2.8	15
106	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 2016, 16, 339.	2.6	15
107	SPAR â€“ a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial. BMC Cancer, 2019, 19, 1229.	2.6	15
108	Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of ¹⁷⁷Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and tumors (pNETS, mNETS).. Journal of Clinical Oncology, 2020, 38, 4608-4608.	1.6	15

#	Article	IF	Citations
109	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biology and Therapy, 2020, 21, 891-898.	3.4	14
110	Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated nonâ€“small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.. Journal of Clinical Oncology, 2022, 40, 102-102.	1.6	14
111	Targeting Mutated KRAS Genes to Treat Solid Tumours. Molecular Diagnosis and Therapy, 2022, 26, 39-49.	3.8	13
112	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Review of Anticancer Therapy, 2014, 14, 1477-1493.	2.4	12
113	Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. Acta OncolÃ³gica, 2016, 55, 480-485.	1.8	12
114	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. PLoS ONE, 2020, 15, e0229900.	2.5	12
115	Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. Clinical Cancer Research, 2021, 27, 52-59.	7.0	12
116	Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.. Journal of Clinical Oncology, 2012, 30, 386-386.	1.6	12
117	First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs).. Journal of Clinical Oncology, 2020, 38, 604-604.	1.6	12
118	Hepatic encephalopathy associated with cancer or anticancer therapy. Gastrointestinal Cancer Research: GCR, 2013, 6, 11-6.	0.7	12
119	A simple, cost-effective and flexible method for processing of snap-frozen tissue to prepare large amounts of intact RNA using laser microdissection. Biochimie, 2012, 94, 2491-2497.	2.6	11
120	â€œWatchful waitingâ€•for metastatic colorectal cancer, antediluvian or an option to be considered again?. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 10-13.	1.1	11
121	Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1907-1924.	3.3	11
122	Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Clinical Therapeutics, 2016, 38, 1376-1391.	2.5	11
123	BRAF Mutation and Its Importance in Colorectal Cancer. , 0, , .		11
124	Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age. Breast Cancer Research, 2020, 22, 90.	5.0	11
125	Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. Current Problems in Cancer, 2021, 45, 100637.	2.0	11
126	Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)â€”Final results.. Journal of Clinical Oncology, 2022, 40, 4122-4122.	1.6	11

#	Article	IF	Citations
127	The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer, 2013, 13, 242.	2.6	10
128	Can we accurately report PTEN status in advanced colorectal cancer?. BMC Cancer, 2014, 14, 128.	2.6	10
129	Liver resection for colorectal cancer metastases: a comparison of outcomes over time in South Australia. Hpb, 2018, 20, 340-346.	0.3	10
130	Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry. Targeted Oncology, 2019, 14, 85-91.	3.6	10
131	Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer, 2011, 11, 313.	2.6	9
132	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. Clinical Colorectal Cancer, 2018, 17, 313-319.	2.3	9
133	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. Clinical Cancer Research, 2021, 27, 2159-2167.	7.0	9
134	Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, 387-387.	1.6	9
135	Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).. Journal of Clinical Oncology, 2012, 30, 388-388.	1.6	9
136	Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.. Journal of Clinical Oncology, 2014, 32, 4101-4101.	1.6	9
137	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 740-740.	1.6	9
138	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2019, 37, 11023-11023.	1.6	9
139	Antitumor Effect of Somatostatin Analogs in Neuroendocrine Tumors. Journal of Clinical Oncology, 2010, 28, e41-e42.	1.6	8
140	The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. Acta OncolÃ³gica, 2014, 53, 877-884.	1.8	8
141	Advanced colorectal cancer treatment options beyond standard systemic therapy. Lancet Oncology, The, 2017, 18, 157-159.	10.7	8
142	Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry. Targeted Oncology, 2020, 15, 751-757.	3.6	8
143	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer, 2010, 9, 8-14.	2.3	7
144	Equivalence of outcomes for rural and metropolitan patients with metastatic colorectal cancer in South Australia. Medical Journal of Australia, 2014, 201, 462-466.	1.7	7

#	Article	IF	Citations
145	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. Expert Review of Anticancer Therapy, 2016, 16, 557-571.	2.4	7
146	BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?. Molecular Diagnosis and Therapy, 2016, 20, 75-82.	3.8	7
147	Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. Future Oncology, 2018, 14, 2437-2459.	2.4	7
148	Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 3838-3844.	7.0	7
149	Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation. Epigenetics, 2019, 14, 158-170.	2.7	7
150	Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. Cancers, 2020, 12, 1715.	3.7	7
151	Curative therapy for rectal cancer. Expert Review of Anticancer Therapy, 2021, 21, 193-203.	2.4	7
152	Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 507-507.	1.6	7
153	VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. Scientific Reports, 2022, 12, 1238.	3.3	7
154	Yttrium 90 Microsphere Selective Internal Radiation Treatment of Hepatic Colorectal Metastases. Archives of Surgery, 2008, 143, 313.	2.2	6
155	Reversing Hyperammonemia in Neuroendocrine Tumors. Journal of Clinical Gastroenterology, 2010, 44, e186-e189.	2.2	6
156	Small Cell Lung Cancer: Patterns of care and their influence on survival â€“ 25â€ƒyears experience of a single Australian oncology unit. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 252-257.	1.1	6
157	<scp>MRI</scp> rectal cancer in Australia and New Zealand: An audit from the <scp>PETACC</scp>â€6 trial. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 607-615.	1.8	6
158	Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis. Expert Review of Anticancer Therapy, 2017, 17, 965-979.	2.4	6
159	Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. Expert Review of Anticancer Therapy, 2018, 18, 339-349.	2.4	6
160	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. JCO Precision Oncology, 2020, 4, 1152-1162.	3.0	6
161	Guillainâ€“Barre syndrome in colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 205-208.	1.1	5
162	Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: Implications for health-care utilization in Australia. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 239-248.	1.1	5

#	Article	IF	Citations
163	Panitumumab in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2013, 13, 781-793.	2.4	5
164	Liver metastases resection for gastric and esophageal tumors: is there enough evidence to go down this path?. Expert Review of Anticancer Therapy, 2016, 16, 1219-1225.	2.4	5
165	Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. Drugs and Aging, 2017, 34, 173-189.	2.7	5
166	Capecitabine in locally advanced anal cancer, do we need randomised evidence?. Expert Review of Anticancer Therapy, 2017, 17, 411-416.	2.4	5
167	Synovial metastasis of the knee in aKRASmutant rectal adenocarcinoma patient. BMJ Case Reports, 2017, 2017, bcr-2017-220008.	0.5	5
168	Outcomes of Older Patients (â‰¥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. Clinical Colorectal Cancer, 2019, 18, e140-e149.	2.3	5
169	Appendiceal neoplasm incidence and mortality rates are on the rise in Australia. Expert Review of Gastroenterology and Hepatology, 2021, 15, 203-210.	3.0	5
170	Immunohistochemistry features and molecular pathology of appendiceal neoplasms. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 369-384.	6.1	5
171	A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. Journal of Clinical Oncology, 2019, 37, 3518-3518.	1.6	5
172	Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. World Journal of Gastroenterology, 2015, 21, 5352.	3.3	5
173	Prognostic differences of RAS mutations: Results from South Australian (SA) metastatic colorectal (mCRC) registry.. Journal of Clinical Oncology, 2020, 38, 4067-4067.	1.6	5
174	Human intestinal spirochetosis and its relationship to sessile serrated adenomas in an Australian population. Pathology Research and Practice, 2016, 212, 751-753.	2.3	4
175	Firstâ€line therapy for metastatic colorectal cancer: Current perspectives and future directions. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 3-14.	1.1	4
176	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 2020, 20, 251-270.	2.4	4
177	Monitoring TNM stage of female breast cancer and survival across the South Australian population, with national and international TNM benchmarking: A population-based cohort study. BMJ Open, 2020, 10, e037069.	1.9	4
178	Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.. Journal of Clinical Oncology, 2019, 37, 638-638.	1.6	4
179	Contrast induced hyperthyroidism due to iodine excess. BMJ Case Reports, 2009, 2009, bcr0620091982-bcr0620091982.	0.5	4
180	Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.. Journal of Clinical Oncology, 2016, 34, 519-519.	1.6	4

#	Article	IF	Citations
181	Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillance. New Zealand Medical Journal, 2017, 130, 57-67.	0.5	4
182	Successfully improving access and accrual to oncology clinical trials. Cancer, 2007, 109, 1451-1453.	4.1	3
183	Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer. Lancet Oncology, The, 2018, 19, 587-589.	10.7	3
184	Survival Outcomes for Patients With Indeterminate 18FDG-PET Scan for Extrahepatic Disease Before Liver Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2018, 267, 929-935.	4.2	3
185	Do we know what to do with our nonagenarian and centenarian patients with metastatic colorectal cancer (mCRC)? Results from the South Australian mCRC registry. Acta OncolÃ³gica, 2018, 57, 1455-1457.	1.8	3
186	Female breast cancer treatment and survival in South Australia: Results from linked health data. European Journal of Cancer Care, 2021, 30, e13451.	1.5	3
187	Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours. BMC Cancer, 2021, 21, 736.	2.6	3
188	Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. JMIR Research Protocols, 2019, 8, e14361.	1.0	3
189	Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry. Targeted Oncology, 2022, 17, 35-41.	3.6	3
190	Chronomodulated Chemotherapy in Advanced Colorectal Carcinoma. Journal of Clinical Oncology, 2002, 20, 3937-3939.	1.6	2
191	Fluorouracil-induced Hepatic Artery Spasm Preventing Yttrium-90 Microsphere Administration. Clinical Nuclear Medicine, 2008, 33, 528-530.	1.3	2
192	FOLFIRI with cetuximab or bevacizumab: FIRE-3. Lancet Oncology, The, 2014, 15, e582-e583.	10.7	2
193	ASPECCT: panitumumab versus cetuximab for colorectal cancer â€“ Authors' reply. Lancet Oncology, The, 2014, 15, e303.	10.7	2
194	A systematic scoping review of determinants of multidisciplinary cancer team access and decision-making in the management of older patients diagnosed with colorectal cancer. Journal of Geriatric Oncology, 2020, 11, 909-916.	1.0	2
195	Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. Clinical Colorectal Cancer, 2021, 20, 245-255.	2.3	2
196	Abstract C33: A twoâ€arm phase 1 clinical trial with NPIâ€0052, a novel proteasome inhibitor. , 2009, , .		2
197	Correlation of PI3KCAand extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).. Journal of Clinical Oncology, 2014, 32, 3539-3539.	1.6	2
198	Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.. Journal of Clinical Oncology, 2014, 32, 3552-3552.	1.6	2

#	Article	IF	Citations
199	Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study.. Journal of Clinical Oncology, 2015, 33, 3533-3533.	1.6	2
200	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, e14623-e14623.	1.6	2
201	A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 results.. Journal of Clinical Oncology, 2019, 37, 4102-4102.	1.6	2
202	Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.. Journal of Clinical Oncology, 2019, 37, 537-537.	1.6	2
203	Type 2 diabetes as a potential risk marker for early onset colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15005-e15005.	1.6	2
204	Immunotherapy use in oesophagogastric cancersâ€"a review of the literature. British Journal of Cancer, 2022, 127, 21-29.	6.4	2
205	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. Targeted Oncology, 2022, 17, 95.	3.6	2
206	ÂGood outcomes of liver transplantation for hepatitis C at a low volume centre. Annals of Hepatology, 2016, 15, 207-14.	1.5	2
207	Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer. Colorectal Cancer, 2012, 1, 137-148.	0.8	1
208	Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies. Colorectal Cancer, 2014, 3, 223-232.	0.8	1
209	BRAF Mutation in Colorectal Cancer. , 0, , .		1
210	Comparable survival outcome of metastatic colorectal cancer in Indigenous and non-Indigenous patients: Retrospective analysis of the South Australian metastatic colorectal cancer registry. Australian Journal of Rural Health, 2016, 24, 85-91.	1.5	1
211	Evidence that decreased expression of sinusoidal bile acid transporters accounts for the inhibition by rapamycin of bile flow recovery following liver ischemia. European Journal of Pharmacology, 2018, 838, 91-106.	3.5	1
212	Moving miRNAs to therapeutic targets in colorectal cancer. EBioMedicine, 2019, 43, 13-14.	6.1	1
213	Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 3-12.	1.1	1
214	The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis. Patient Education and Counseling, 2021, 105, 212-220.	2.2	1
215	A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).. Journal of Clinical Oncology, 2013, 31, e14506-e14506.	1.6	1
216	Meta-analysis of outcomes of VEGF and EGFR targeted biologic therapy in relapsed metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 534-534.	1.6	1

#	Article	IF	Citations
217	Right (R) or left (L) primary site of colorectal cancer and outcomes for metastatic colorectal cancer (mCRC): Results from the south Australian registry of mCRC.. Journal of Clinical Oncology, 2014, 32, 596-596.	1.6	1
218	The management of colorectal cancer (CRC) liver metastases with yttrium-90 microspheres (Y90): The south Australian (SA) experience.. Journal of Clinical Oncology, 2014, 32, 666-666.	1.6	1
219	Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 3586-3586.	1.6	1
220	Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT.. Journal of Clinical Oncology, 2015, 33, 3587-3587.	1.6	1
221	Survival impact of primary tumor resection in patients (pts) with unresectable metastatic colorectal cancer (mCRC): Findings from the South Australian Metastatic Colorectal Cancer Registry (SAMCRC).. Journal of Clinical Oncology, 2015, 33, e14675-e14675.	1.6	1
222	Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. Journal of Clinical Oncology, 2018, 36, 3534-3534.	1.6	1
223	COVID-19 prompts rapid and safe transition of chemotherapy into homes. Australian Health Review, 2021, , .	1.1	1
224	Assessment of IL-6, IL-8, bFGF, PDGF-BB, and VEGF-A as prognostic and predictive biomarkers for anti-VEGF in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 502-502.	1.6	1
225	Patterns of care and outcomes for young patients (age < 40) with metastatic colorectal cancer (mCRC): Findings from a population-based registry.. Journal of Clinical Oncology, 2014, 32, e17584-e17584.	1.6	1
226	A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.. Journal of Clinical Oncology, 2017, 35, 643-643.	1.6	1
227	Patterns of care for synchronous rectal cancer with liver-only metastasis: Results from the South Australian registry of metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 701-701.	1.6	1
228	Insights From the IDEA Collaboration: Are They Enough?. Journal of Clinical Oncology, 2022, , JCO2102975.	1.6	1
229	Response to: Perioperative Morbidity Affects the Long-Term Survival in Patients Following Liver Resection for Colorectal Metastases. Journal of Gastrointestinal Surgery, 2009, 13, 180.	1.7	0
230	Age and treatment choices in advanced colorectal cancer. Colorectal Cancer, 2012, 1, 343-351.	0.8	0
231	Second-line therapy for metastatic colorectal cancer. Lancet Oncology, The, 2015, 16, 476-477.	10.7	0
232	Optimal therapy for resectable rectal cancer. Expert Review of Anticancer Therapy, 2016, 16, 285-302.	2.4	0
233	Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients. Medical Care, 2017, 55, 86-86.	2.4	0
234	Response to: â€œConsideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastasesâ€. Annals of Surgery, 2018, 268, e9-e10.	4.2	0

#	Article	IF	Citations
235	Local Treatment Options for Unresectable Liver Metastases in Colorectal Cancer. , 0, , .		0
236	Authorsâ€™ Reply to Yu: â€œOutcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registryâ€: Targeted Oncology, 2019, 14, 367-368.	3.6	0
237	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2020, 20, 305-324.	2.4	0
238	Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells. Breast Cancer Research and Treatment, 2021, 187, 681-693.	2.5	0
239	Phase I study of autolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium.. Journal of Clinical Oncology, 2021, 39, 4115-4115.	1.6	0
240	Do patients with metastatic colorectal cancer (mCRC) with late relapse after curative surgery have a better survival?. Journal of Clinical Oncology, 2012, 30, 558-558.	1.6	0
241	Persistent oxaliplatin (OX) induced peripheral neuropathy in patients (pts) with colorectal cancer: A descriptive study.. Journal of Clinical Oncology, 2012, 30, e19513-e19513.	1.6	0
242	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. Journal of Clinical Oncology, 2013, 31, e14501-e14501.	1.6	0
243	Medical Oncology. , 2014, , 71-82.		0
244	The efficacy and safety outcomes of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the AGITG MAX clinical trial and in nontrial patients in two cancer centers.. Journal of Clinical Oncology, 2014, 32, 595-595.	1.6	0
245	A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 547-547.	1.6	0
246	Survival improvements associated with access to biologic agents: Results from the South Australian (SA) Metastatic Colorectal (mCRC) Registry.. Journal of Clinical Oncology, 2014, 32, e17616-e17616.	1.6	0
247	Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.. Journal of Clinical Oncology, 2014, 32, 3609-3609.	1.6	0
248	Survival for patients with resectable lung metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 708-708.	1.6	0
249	Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.. Journal of Clinical Oncology, 2015, 33, 705-705.	1.6	0
250	Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 566-566.	1.6	0
251	Survival improvement associated with access to biological agents: Updated results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.. Journal of Clinical Oncology, 2015, 33, e14576-e14576.	1.6	0
252	Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17.. Journal of Clinical Oncology, 2016, 34, 256-256.	1.6	0

#	Article	IF	Citations
253	Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.. Journal of Clinical Oncology, 2016, 34, 3538-3538.	1.6	0
254	Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: A retrospective analysis of NCIC CTG CO.17.. Journal of Clinical Oncology, 2016, 34, e15025-e15025.	1.6	0
255	Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, e15050-e15050.	1.6	0
256	Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2017, 35, 699-699.	1.6	0
257	Metastatic colorectal cancer (mCRC) and micro-satellite instability.. Journal of Clinical Oncology, 2018, 36, e15510-e15510.	1.6	0
258	Phase I trial of nab-paclitaxel administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma (ART in LAP).. Journal of Clinical Oncology, 2020, 38, e16796-e16796.	1.6	0
259	Regorafinib outcomes from the population-based South Australian mCRC registry (SAmCRCR).. Journal of Clinical Oncology, 2020, 38, e19344-e19344.	1.6	0
260	Cohort 1 results of a phase I study of autolytic immunotherapy of metastatic neuroendocrine neoplasms using intralesional rose bengal disodium.. Journal of Clinical Oncology, 2020, 38, e16694-e16694.	1.6	0
261	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2022, 22, 39-51.	2.4	0
262	Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 428-433.	1.1	0
263	403â€...Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors. , 2020, , .		0
264	SPAR: A randomized placebo-controlled phase 2 trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: An AGITG clinical trial.. Journal of Clinical Oncology, 2022, 40, TPS3646-TPS3646.	1.6	0